Movement Alert｜Liquidia Technologies Inc Rises 9.07% in Regular Trading, Yutrepia Gains Fast Track Designation from FDA

Market Focus

Yesterday

On October 8, Liquidia Technologies Inc rose 9.07% in regular trading, trading at $29.01 per share, with turnover of $33.38 million. The catalyst was the U.S. FDA granting Fast Track designation to Yutrepia inhaled powder for the treatment of systemic sclerosis-associated Raynaud's phenomenon, marking an important expansion beyond pulmonary arterial hypertension.

The Fast Track designation is designed to expedite development and review of therapies for serious conditions, enabling more frequent communication with the FDA and the possibility of priority review. Additionally, Yutrepia achieved net product sales of approximately $170.4 million in the second quarter, up 31% sequentially, indicating continued strong commercial momentum.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1141852064"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1141852064\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1141852064?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-10-08 22:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1141852064","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Liquidia Technologies Inc Rises 9.07% in Regular Trading, Yutrepia Gains Fast Track Designation from FDA","media":"Market Focus","content":"<p><p>On October 8, Liquidia Technologies Inc rose 9.07% in regular trading, trading at $29.01 per share, with turnover of $33.38 million. The catalyst was the U.S. FDA granting Fast Track designation to Yutrepia inhaled powder for the treatment of systemic sclerosis-associated Raynaud's phenomenon, marking an important expansion beyond pulmonary arterial hypertension.</p><p>The Fast Track designation is designed to expedite development and review of therapies for serious conditions, enabling more frequent communication with the FDA and the possibility of priority review. Additionally, Yutrepia achieved net product sales of approximately $170.4 million in the second quarter, up 31% sequentially, indicating continued strong commercial momentum.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Liquidia Technologies Inc Rises 9.07% in Regular Trading, Yutrepia Gains Fast Track Designation from FDA</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Liquidia Technologies Inc Rises 9.07% in Regular Trading, Yutrepia Gains Fast Track Designation from FDA\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-10-08 22:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On October 8, Liquidia Technologies Inc rose 9.07% in regular trading, trading at $29.01 per share, with turnover of $33.38 million. The catalyst was the U.S. FDA granting Fast Track designation to Yutrepia inhaled powder for the treatment of systemic sclerosis-associated Raynaud's phenomenon, marking an important expansion beyond pulmonary arterial hypertension.</p><p>The Fast Track designation is designed to expedite development and review of therapies for serious conditions, enabling more frequent communication with the FDA and the possibility of priority review. Additionally, Yutrepia achieved net product sales of approximately $170.4 million in the second quarter, up 31% sequentially, indicating continued strong commercial momentum.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LQDA","symbol_name":"Liquidia Technologies Inc","start_time":0,"source_url":"","article_id":"1141852064","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1141852064","pubTimestamp":1791469044,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On October 8, Liquidia Technologies Inc rose 9.07% in regular trading, trading at $29.01 per share, with turnover of $33.38 million. The catalyst was the U.S. FDA granting Fast Track designation to...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LQDA":"Liquidia Technologies Inc"},"translate_title":"走势警报|Liquidia Technologies Inc 常规交易上涨 9.07%，Yutrepia 获得 FDA 快速通道认证","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LQDA":1},"content_text":"On October 8, Liquidia Technologies Inc rose 9.07% in regular trading, trading at $29.01 per share, with turnover of $33.38 million. The catalyst was the U.S. FDA granting Fast Track designation to Yutrepia inhaled powder for the treatment of systemic sclerosis-associated Raynaud's phenomenon, marking an important expansion beyond pulmonary arterial hypertension.The Fast Track designation is designed to expedite development and review of therapies for serious conditions, enabling more frequent communication with the FDA and the possibility of priority review. Additionally, Yutrepia achieved net product sales of approximately $170.4 million in the second quarter, up 31% sequentially, indicating continued strong commercial momentum.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}